{"id":"W3128792891","doi":"10.1016/j.annonc.2021.01.065","title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Exelixis; Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Internal medicine; Tolerability; Oncology; Taxane; Cohort; Breast cancer; Cancer; Adverse effect; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002724106,0.0003278402,0.001902673,0.0001097753,0.00007169753,0.000006518456,0.0001406414,0.000140276,0.0001441581],"category_scores_gemma":[0.0001966919,0.0001869722,0.0003801842,0.0003747208,0.0002729294,0.000009934307,0.00004655122,0.00005315009,3.09101e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005782236,"about_ca_system_score_gemma":0.002022501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002082263,"about_ca_topic_score_gemma":0.00207969,"domain_scores_codex":[0.9980174,0.0002710352,0.000671901,0.0005146915,0.0002057687,0.0003192208],"domain_scores_gemma":[0.9974654,0.0002912185,0.0007943686,0.0003703652,0.0009535929,0.0001250191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9484727,0.006659109,0.00009135653,0.00008903557,0.007262538,0.00002235997,0.0002953979,0.0002826439,0.002847428,0.000009860552,0.00012393,0.03384368],"study_design_scores_gemma":[0.816219,0.1041459,0.00005738833,0.00005139804,0.001953895,0.00001522354,0.00008666005,0.0001787045,0.07279265,0.00001830578,0.004241634,0.0002391725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913441,0.0002326494,0.003245017,0.0005769699,0.00007679681,0.003434172,0.0008627647,0.00001095544,0.000216575],"genre_scores_gemma":[0.9883276,0.001387665,0.005892632,0.000621265,0.00008992747,0.001450897,0.0007481279,0.00005238006,0.001429549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1322536,"threshold_uncertainty_score":0.7624505,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03530508733216457,"score_gpt":0.3644163185437791,"score_spread":0.3291112312116145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}